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Abstract
Data on the long-term metabolic side-effects associated with antipsychotics are scarce. Prospective longitudinal
studies in medication-naive patients with a first episode of psychosis are a valuable source of information as
they provide an assessment prior to the antipsychotic exposure and minimize the effect of potential confounding
factors. The aim of this study was to assess the course of weight gain and the incidence of metabolic abnormal-
ities during the first 3 yr of antipsychotic treatment. Data were collected from a cohort of 170 first-episode
psychosis patients. They were randomly assigned to haloperidol (32%); olanzapine (32%) and risperidone
(36%). The dose used was flexible. The initial antipsychotic treatment was changed when required, based on
clinical response and tolerability. The results showed that the mean weight gain at 3 yr was 12.1 kg (S.D.=
10.7). It appeared to increase rapidly during the first year (85% of the total mean weight gain) and then stabilized
gradually over time. Total cholesterol, LDL-cholesterol and triglyceride levels followed a similar trajectory with
a significant increase only during the first year. No significant changes were detected in the mean values of gly-
caemic parameters. Two patients with a family history of diabetes developed diabetes type II. At short-term the
factors positively associated with weight gain were lower body mass index, male gender and olanzapine treat-
ment. At long-term, functional status and clinical response were the main predictors. The results of our study
indicate that the first year of antipsychotic treatment is a critical period for weight gain and metabolic changes.
Identification of weight gain patterns may help to inform studies that aim to prevent or mitigate the metabolic
adverse events associated with antipsychotic therapy.
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Introduction
People with schizophrenia and other serious mental
illness live up to 25 yr less than the general population
(Saha et al., 2007), with cardiovascular disease being the
most frequent cause of death (Mackin and McAllister-
Williams, 2006). Antipsychotic therapy among other
factors (such as smoking, unhealthy lifestyle or reduced
access to care) has been reported to account for this excess
of mortality (De Hert et al., 2011). However, the attri-
butable cardiovascular mortality risk associated with
antipsychotic therapy is difficult to estimate due to the
inherent problems in carrying out long-term prospective
studies in patients with first-episode psychosis.
Weight gain and metabolic abnormalities are major
concerns of antipsychotic therapy in clinical practice.
Patients with a first episode of psychosis who have not
been previously treated are particularly susceptible to
antipsychotic adverse reactions (Tarricone et al., 2010).
According to most guidelines and current clinical prac-
tice, after a first episode of psychosis, antipsychotic main-
tenance treatment is recommended for 2 yr, oscillating
between a minimum of 1 yr to indefinite duration.
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Unfortunately, the majority of data available regarding
weight gain and metabolic adverse reactions are based
on short-term clinical trials. There are very few studies
with a follow-up of 2 yr or longer (Gentile, 2006;
De Hert et al., 2008; Foley and Morley, 2011) and the
full magnitude and frequency of these adverse effects
are difficult to establish.
Data from retrospective observational studies have
shown that patients under long-term antipsychotic treat-
ment have a higher incidence of obesity, diabetes and
dyslipidaemia than the general population (Newcomer,
2005; De Hert et al., 2011). It has been suggested that
the incidence of metabolic abnormalities might be over-
estimated. The findings of these studies could be poten-
tially biased if only those patients with a more severe
disease have been screened. In addition, these types of
research studies rely on the quality of data already col-
lected and they may not have enough information to con-
trol for confounding factors (Holt and Peveler, 2006).
The aim of this study was to assess the course of
weight gain and metabolic disturbances associated
with long-term antipsychotic treatment. A 3-yr follow-up
prospective cohort study was conducted in a medication-
naive first-episode psychosis population. We have also
explored the predictive value of clinical factors on weight
gain.
Method
The study was conducted in the outpatient and inpatient
psychiatric services of Marques de Valdecilla University
Hospital, Spain. The hospital is a reference centre of a
catchment area population of 555000 people and pro-
vides the only psychiatric ward and 24 h emergency
care for the whole province. A more detailed description
of the study population has been previously reported
(Pelayo-Terán et al., 2008). The study protocol was
approved by the ethics committee of the Marques de
Valdecilla University Hospital.
Study design
Patients recruited into this study were drawn from a
consecutive sample of psychotic patients enrolled in our
first-episode psychosis programme from February 2001
to February 2005. Patients had to meet the following
criteria: (1) age 15–60 yr; (2) living in the catchment
area; (3) experiencing their first episode of psychosis; (4)
never treated with antipsychotic medication; (5) meeting
DSM-IV criteria for brief psychotic disorder, schizophre-
niform disorder, schizophrenia or schizoaffective dis-
order; and (6) they understood the nature of the study
and signed an informed consent document. Patients
were excluded for any of the following reasons: (1) meet-
ing DSM-IV criteria for drug dependence; (2) meeting
DSM-IV criteria for mental retardation; and (3) having a
serious medical illness. The diagnoses were confirmed
according to the DSM-IV criteria, using the Structured
Clinical Interview for DSM-IV (SCID-I) by an expert
psychiatrist after 6mth from the initial contact.
At inclusion patients were randomly assigned to
receive haloperidol, olanzapine or risperidone. The dose
was flexible, based on response and tolerability. Those
patients who did not respond after 6 wk or who had sig-
nificant drug adverse reactions were changed to a differ-
ent antipsychotic. The lowest effective dose was sought
in maintenance treatment.
Certain concomitant medications (lormetazepam
and clonazepam) were permitted for the management
of agitation, anxiety and/or insomnia. Only if clinically
significant extrapyramidal signs occurred, anticholinergic
medication was allowed (biperiden up to 8mg/day).
Antidepressants (sertraline) and mood stabilizers
(lithium) were permitted if clinically needed. Advice on
diet, exercise and lifestyle was given to all patients.
Laboratory assessments
Fasting venous blood samples were collected between
08:00 and 10:00 at baseline, 3 mth and yearly thereafter
for 3 yr.
All determinations were performed in our hospital,
including both biochemical and endocrinology analysis.
Glucose, total cholesterol, HDL cholesterol, and tri-
glycerides were measured by automated methods on
a Technicon Dax (Technicon Instruments Corp, USA),
using the reagents supplied by Boehringer-Mannheim
(Germany). Low-density lipoprotein (LDL) cholesterol
was determined by the Friedewald et al., calculation
(Friedewald et al., 1972): LDL=total cholesterol – (HDL+
[triglycerides/5]).
In addition, a complete blood count and liver function
tests based on standard haematological and clinical
chemistry values were performed at each visit (data not
shown).
Insulin levels were measured by an immunoradio-
metric assay (IRMA) (Immunotech, Beckman Coulter
Company, Czech Republic) with an average interassay
coefficient of variation (CV) of 3.3% and intraassay
CV of 2.8%. The sensitivity of method was 0.5 μU/ml.
Values for normal weight subjects are 2.1–22 μU/ml.
This assay does not show any cross-reactivity with
human proinsulin and C-peptide.
Homeostasis model assessment (HOMA) was used
to assess insulin resistance (IR). The HOMA index
was calculated by means of a previously described
formula (Matthews et al., 1985): HOMA=[fasting insulin
(μU/ml)× fasting glucose (mmol/l)]/22.5. In addition, as
proposed by McLaughlin et al. (2005), we calculated the
triglyceride/HDL cholesterol (TG/HDL cholesterol) ratio
as a predictor of insulin resistance using the cut-point of
3.5 described by them as optimal.
Serum leptin concentrations were measured by specific
radioimmunoassay using a commercial kit (Linco
Research, USA). The detection limits was 0.5 ng/ml, the
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intra-assay CV was 4.5% and the interassay CV was 5.2%.
This assay does not show any cross-reactivity with insu-
lin, proinsulin, C peptide, glucagon or insulin-like growth
factor I. Values in subjects with normal body mass index
(BMI) were <10 ng/ml for men and <20 ng/ml for women.
Clinical assessments
The presence of positive and negative psychotic symp-
toms was assessed by the Scale for the Assessment of
Positive Symptoms (SAPS) (Andreasen, 1983) and the
Scale for the Assessment of Negative Symptoms (SANS)
(Andreasen, 1981), respectively. Symptomatic response
for positive or negative symptoms was defined as a
reduction of at least 40% of the total SANS or SAPS
score from baseline and a total SANS or SAPS score 48
and individual items scoring <3. If symptoms were
present, they were only mild and they did not interfere
with daily functioning.
Functional status was determined by the Spanish
version of the Disability Assessment Scale (DAS) (Mana
and Giron, 1998) at baseline, 1 yr and 3 yr follow-up.
A psychiatrist and a social worker assessed the patient
and their relatives independently. A consensus reach by
both on global functioning was used to classify the par-
ticipants into two subgroups: patients with ‘good global
functioning’ (scored=0=no disability) and patients with
‘functional deficits’ (scored from 1=minimal disability
to 5=extreme disability).
Statistical analyses
To evaluate the changes over time of weight, BMI,
lipid and glycaemic measurements, repeated-measures
analyses of variance (ANOVA) followed by post-hoc
Bonferroni tests were used. The level of statistical
significance for all tests was set a priori at p<0.05.
Backwards step-wise linear regression analyses were
conducted to assess the association between antipsycho-
tic-induced weight gain and clinical factors. Candidate
variables included at the initial stage of the analysis
were BMI at baseline, age, sex, socioeconomic level (low
vs. middle-high), initially assigned treatment (haloperi-
dol, olanzapine or risperidone), duration of untreated
psychosis (log-transformed), hospitalization after the
first episode of psychosis, positive and negative psychotic
symptoms and social functioning (deficit vs. non-deficit).
In the preliminary analyses we also included smoking sta-
tus (smoker vs. non-smoker) and diagnosis (schizo-
phrenia/schizophreniform vs. other diagnosis) but they
were omitted in the final models since they were found
not to be significant. The analyses were conducted at
3mth, 1 yr and 3 yr follow-up.
Finally, the McNemar test for repeated measures was
used to compare the number of patients with high levels
of lipid and glycaemic values (according to the reference
values of our laboratory) at baseline and after 3 yr of
antipsychotic treatment.
All statistical analysis were performed with the SPSS
software package for Windows (version 16.0).
Results
Characteristics of the cohort
A detailed description of the clinical and sociodemo-
graphic characteristics of the study population has
been previously reported (Crespo-Facorro et al., 2006).
A total of 174 patients enrolled in the first episode psy-
chosis programme of Cantabria were included in this
clinical trial. Data on the main metabolic variables
were available in 170 participants at baseline and in
135 of them at 3 yr (80% of the initial sample). The
main reasons for discontinuation were: patient’s decision
13% (n=23); moving to another city 4% (n=7); suicide (n=1);
prison (n=1); and, moving to long-term psychiatric
facilities (n=3).
The patients had a mean age of 27.3 (S.D. =7.8), 61%
were male and most of them were white Caucasian
(97%). At 6-mth follow-up, 62% had a diagnosis of schizo-
phrenia, 2% schizoaffective, 23% schizophreniform,
5% brief psychotic episode and 8% unspecified psychotic
disorder. Sixty per cent belonged to a low—middle
socioeconomic status and 84% lived with family.
At baseline the patients were randomly assigned to
receive haloperidol (32%), olanzapine (32%) or risperi-
done (36%). At 1 yr, 67% of the patients who completed
the follow-up continued with the same treatment, at
2 yr 53% and at 3 yr the number decreased to 43%. The
mean time to discontinuation was 15.4mth (95% confi-
dence interval (CI), 11.8–18.8) for haloperidol, 23.8 mth
(95% CI, 20.1–27.4) for olanzapine and 20.7mth
(95% CI, 17.2–24) for risperidone. At the end of the
follow-up 88% patients were taking second-generation
antipsychotics. Prescribed antipsychotics were as follows:
10% haloperidol; 31% olanzapine; 35% risperidone; 7%
quetiapine; 6% ziprasidone; 2% amisulpride; 4% cloza-
pine; 3% aripiprazole and 2% other antipsychotics.
Results comparing the metabolic side effects of the initial
treatments at 3 mth (Perez-Iglesias et al., 2007) and 1 yr
have been already published (Perez-Iglesias et al., 2008).
No significant differences among treatments were found
at 1-yr follow-up.
Course of weight gain, glycaemic and lipid levels
The mean weight gain during the first 3 yr of antipsy-
chotic treatment was 12.1 kg (S.D.=10.7). The majority
(78%) of the patients experienced a clinically significant
weight gain (>7% of their baseline body weight). The per-
centage of obese (BMI>30 kg/m2) patients rose from 4 to
31% at the end of the 3 yr follow-up. The 50th percentile
was 10.6 kg.
The maximum increase in weight occurred within the
first 12mth (85% of the mean weight gain and 86% of
the mean increase in BMI (see Table 1). The leptin plasma
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Weight (kg) 67.2 (12.7) 168 72.5 (13.4) 154 77.5 (15.3) 152 77.9 (15.0) 134 79.9 (16.4) 136 58.1 4, 117 <0.001 0.665
BMI (kg/m2) 23.2 (3.5) 163 25.1 (3.5) 153 26.9 (4.4) 152 27.1 (4.7) 134 27.7 (4.9) 136 58.6 4, 117 <0.001 0.667
Lipid profile
TC (mg/dl) 173.7 (41.4) 170 188.9 (36.8) 132 196.6 (38.6) 151 192.1 (34.1) 135 189.7 (39.3) 141 13.6 4, 99 <0.001 0.354
LDLc (mg/dl) 109.7 (42.8) 145 119.9 (31.1) 130 123.9 (32.9) 148 122.5 (30.4) 130 119.8 (32.6) 136 8.1 4, 87 <0.001 0.272
HDLc (mg/dl) 50.2 (14.2) 144 49.3 (13.8) 130 49.7 (13.4) 149 46.9 (13.0) 131 47.8 (14.8) 138 4.7 4, 90 0.002 0.174
Triglycerides (mg/dl) 86.7 (40.5) 143 98.7 (51.3) 128 121.8 (99.7) 148 114.9 (55.6) 131 115.8 (73.0) 138 9.4 4, 85 <0.001 0.306
TC/HDLc 3.6 (0.8) 143 4.0 (0.9) 129 4.2 (1.1) 149 4.3 (1.2) 131 4.3 (1.3) 139 17.4 4, 89 <0.001 0.438
Glycaemic parameters
Glucose (mg/dl) 87.1 (9.8) 170 87.7 (7.7) 133 88.3 (10.3) 149 87.9 (11.1) 135 89.5 (11.4) 140 0.8 4, 97 0.543 0.031
HOMA index 1.7 (1.5) 137 1.9 (1.4) 125 2.2 (2.3) 145 4 (1.8) 124 2.4 (2.2) 126 1.9 4, 75 0.123 0.091
TG/HDLc index 1.9 (1.1) 137 2.2 (1.5) 126 2.8 (2.9) 148 2.7 (1.7) 130 2.8 (2.3) 138 9.9 4, 80 <0.001 0.330
Insulin total (μU/ml) 7.9 (6.8) 139 8.9 (6.1) 125 10.4 (10.0) 148 10.6 (7.2) 126 10.6 (7.2) 128 2.0 4, 79 0.105 0.091
Insulin men 8.0 (7.6) 87 9.5 (6.9) 76 10.6 (11.1) 90 11.1 (7.2) 79 11.2 (7.7) 80 1.7 4, 51 0.174 0.115
Insulin women 7.7 (5.3) 52 7.9 (4.4) 49 10.1 (8.1) 58 9.8 (7.0) 47 9.6 (6.0) 48 1.6 4, 24 0.203 0.212
Hormonal levels
Leptin total (ng/ml) 7.6 (7.8) 132 10.9 (9.3) 127 13.5 (11.0) 151 13.1 (11.8) 126 12.3 (10.9) 133 24.4 4, 81 <0.001 0.546
Leptin men (ng/ml) 4.6 (4.9) 82 7.5 (6.9) 78 9.0 (7.4) 92 8.5 (7.3) 79 8.4 (6.8) 81 18.1 4, 50 <0.001 0.592
Leptin women (ng/ml) 12.5 (9.2) 50 16.3 (10.1) 49 20.6 (11.9) 59 20.8 (13.9) 47 18.4 (13.3) 52 11.0 4, 27 <0.001 0.619
* Pillai’s Trace statistic F value.







levels, as an indicator of adipose mass, followed a similar
trajectory with a significant increase only during the first
12mth (see Fig. 1).
In a similar way, the plasma total cholesterol, LDL-
cholesterol and triglycerides concentrations increased
significantly within the first year and remained relatively
constant during the rest of the study period (see Fig. 2).
On the contrary, HDL plasma levels remained unchanged
during the first months and decreased significantly
during the last 2 yr.
The weight increase was significantly correlated with
the changes in triglyceride (r=0.34; p<0.001), LDL-C
(r=0.22; p=0.024), leptin (r=0.47; p<0.001) and insulin
(r=0.36; p<0.001) concentrations. There was a negative
correlation between weight gain and the reduction of
the HDL-cholesterol levels (r=−0.34; p<0.001). These
associations were significant after controlling for sex,
age and BMI at baseline.
No significant changes were observed in the mean
glucose plasma levels during the first 3 yr of antipsychotic
treatment. No statistically significant changes were
observed in the mean insulin plasma levels or in the
HOMA index, although a trend for an increase was
noted during the first 12mth (see Table 1 and Fig. 3).
Predictors of weight gain
The regression analyses revealed that at short-term
(3mth) a higher risk of weight gain was associated with
individuals who initially received olanzapine treatment
(β=0.185; t=2.491; p=0.014), male gender (β=0.288;
t=3.778; p<0.001) and those patients with a lower BMI
(β=−0.285; t=−3.648; p<0.001). These variables accounted
for 19% of the variance in weight gain. More detailed
information about the predictive regression models is
available on request.
After 12mth these associations were no longer
detected and the only clinical variable marginally associ-
ated with weight gain was poor social functioning
(β=0.159; t=1.957; p=0.052).
At long-term (3 yr), one of the strongest predictors
of weight gain was poor social functioning (β=0.246;
t=2.441; p<0.016). Those patients with no deficits at 3 yr
follow-up gained a mean of 9.4 kg compared to 14.5 kg
of those patients with deficits in social function (F=4.758;
df=126, 1; p=0.031). The lack of clinical response was
also a significant predictor of weight gain. The lack of
response for negative symptoms was positively associ-























































































Fig. 1. Mean values of anthropometric measurements and leptin levels at each five points. Error bars represent S.E.M. (standard
error of the mean). *=p value <0.05 (one-way ANOVA repeated measures followed by Bonferroni post hoc test with the 1 yr value
[ref] as the reference time-point).
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On the other hand, the subgroup of patients classified
as non-responders for positive symptoms gained sig-
nificantly less weight at the end of the follow-up
(β=−0.301; t=−3.525; p<0.001).
Variables that were not associated with weight gain
were age, socio-economic status and duration of untreated
psychosis.
Incidence of high levels of cholesterol and glucose over
3 yr of antipsychotic treatment
The percentage of patients with clinically elevated tri-
glyceride levels (>150mg/dl) increased from 4.5 to 22.5%
during the 3 yr period (see Table 2). Only one patient
had TG levels higher than 500mg/dl at 1 yr follow-up
and he required triglyceride-lowering medications.
The percentage of patients with HDL-cholesterol below
35 also increased significantly from 7.1 to 23% (p<0.001).
No significant changes were observed over the 3 yr
interval in the percentage of patients with high total
cholesterol or LDL-cholesterol levels (see Table 2).
At baseline one patient had fasting glucose plasma
levels above 126mg/dl, which was not confirmed by sub-
sequent tests. Two individuals developed diabetes type II
(fasting glucose plasma level >126mg/dl) near the end of
the study period and were treated with oral anti-diabetic
drugs. They had been initially assigned to olanzapine and
haloperidol treatment arms and at the time the hyper-
glycaemia was detected they were taking ziprasidone
and amisulpride, respectively. BMI increased from 27.2
to 45.1 kg/m2 in one case and from 30.5 to 36.5 kg/m2 in
the second. Both had first-degree relatives with type II
diabetes.
Other CVD risk factors: tobacco use
The percentage of smokers was very high at baseline
(59%) and at the end of the follow-up (64%). The smoking
prevalence was higher in men (75%, n=63) than in
women (45%; n=24). The mean number of cigarettes
smoked a day was similar in males (23 cig/d) and females
(22 cig/d).
Discussion
Course of weight gain and metabolic changes
This study allows us to see the 3-yr weight gain trajectory
of patients treated with antipsychotic drugs for the first
time. The results indicate that the first 12mth of treatment
is a critical period for weight gain and metabolic changes.
Interventions that aim to prevent or attenuate these
































































































Fig. 2. Mean lipid values at each five points. Error bars represent S.E.M. (standard error of the mean). *=p value <0.05 (one-way
ANOVA repeated measures followed by Bonferroni post hoc test with the 1 yr value [ref] as the reference time-point).














































































Fig. 3. Mean glycaemic values at each five points. Error bars represent S.E.M. (standard error of the mean). *=p value <0.05 (one-way
ANOVA repeated measures followed by Bonferroni post-hoc test with the one year value [ref] as the reference time point).
Table 2. Comparison of proportion of subjects with pathologic parameters in weight,





% (n) N valid p*
Obesity
BMI>30 kg/m2 5.2 (7) 31.9 (43) 135 <0.001
Dyslipidaemia
Cholesterol (mg/dl) >240 6.4 (9) 7.9 (11) 140 0.754
LDL cholesterol (mg/dl) >175 5.3 (6) 5.3 (6) 113 1
HDL cholesterol (mg/dl) <35 7.1 (8) 23 (26) 113 0.001
Triglycerides (mg/dl) >150 4.5 (5) 22.5 (25) 111 <0.001
TC/HDLc ratio >5 8 (9) 29.5 (33) 112 <0.001
Glucose abnormalities
Glucose >126mg/dl 0.7 (1) 1.4 (2) 139 1
Glucose >100mg/dl 5 (7) 9.4 (13) 139 0.238
Tobacco use
Smokers 58.8 (80) 64 (87) 136 0.210
*McNemar test for repeated measures.
Abbreviations: BMI: body mass index, LDL: low-density lipoprotein, HDL: high-density
lipoprotein, TC: total cholesterol.
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The antipsychotic-induced weight gain course has
rarely been investigated beyond the first year (Gentile,
2009). Zipursky et al., (2005) found similar results in a
cohort of patients with first-episode psychosis treated
with haloperidol and olanzapine. Both treatment groups
gained weight rapidly during the first wk of treatment
and then the rate of weight gain slowed gradually and
stabilized after 1yr. Although the total amount of weight
gain is usually lower in chronic populations than in
patients with a first episode of psychosis, a similar pattern
has been observed. In a large 3-yr prospective study of
schizophrenia patients, Novick et al., (2009) reported
that most of the weight gain occurred within the first
6 mth of treatment with different atypical antipsychotics.
Our results are also consistent with the findings obtained
by Kinon et al., (2001) in a retrospective study showing
that patients treated with olanzapine reached a plateau
after the initial 39 wk. In a 5-yr naturalistic study in
patients treated with risperidone Neovius et al. (2007)
found that the weight trajectory was steeper initially
and then tapered off after 2 yr.
As previously reported in this cohort (Perez-Iglesias
et al., 2009), the changes in lipid, insulin and leptin con-
centrations are significantly correlated with weight gain.
The data suggest that interventions targeting weight
gain may also prevent lipid and glycaemic abnormalities.
Predictors of weight gain
Predictors of weight gain at short-term were different
from those at long-term. The inverse association between
pre-treatment BMI and weight gain has been found in
most (Kinon et al., 2001; Brecher et al., 2007; Neovius
et al., 2007; Strassnig et al., 2007; Saddichha et al., 2008)
but not all previous studies (Zipursky et al., 2005;
Ahmed et al., 2008). Initially men gained more weight
than women, which has been also reported by Ahmed
et al., (2008). On the contrary, other studies have found
a higher risk of weight gain in females (McEvoy et al.,
2007; Neovius et al., 2007) or no sex differences
(Zipursky et al., 2005). The finding that patients treated
with olanzapine gained more weight during the first
wk of treatment has been consistently reported in the
literature (Allison et al., 1999; Newcomer, 2005). These
short-term predictors might help to identify a sub-group
of subjects particularly susceptible to rapid weight gain
and who may benefit from early intervention.
At long-term, social functioning was one of the main
factors associated with weight gain. The relationship
between antipsychotic-induced weight gain and social
outcomes has not been as well studied as the other vari-
ables. This finding is in agreement with a previous
study in patients with personality disorder that reported
an association between higher BMI and poor social and
functional outcomes (Frankenburg and Zanarini, 2011).
It is also consistent with the findings reported by Egger
et al., (2007) which showed an improvement in social
functioning linked to weight loss in a sample of patients
receiving topiramate as a therapy to treat
olanzapine-induced weight gain. The adverse impact of
poor social functioning on body weight in people suffer-
ing from schizophrenia is an important area to explore in
the future.
Clinical response was also associated with weight gain
at 3 yr follow-up. The lack of response for positive symp-
toms was negatively correlated with weight gain and the
lack of response for negative symptoms was positively
correlated with weight gain. From these results we can
speculate that those patients with more severe negative
symptoms might have a lower level of physical and social
activities and therefore they would be at higher risk of
weight increase. The finding that those patients with
more severe positive symptoms gained significantly less
weight maybe in part explained by the lower rate of
good adherence by patients in this group (52% of good
compliance in non-responding patients vs. 75% in
patients with good response).
Overall, weight gain was modestly predicted by the
main clinical variables in our sample. Changes in body
weight are the result of complex interactions between
environmental and genetic factors. A possible explanation
for the limited prediction of these models may be the lack
of inclusion of other variables such us diet, level of phys-
ical activity or genetic factors that could influence the
amount of weight gain.
Cardiovascular risk factors
It is worth noting that the incidence of type II diabetes in
our cohort (5 cases per 1000 person-year) was similar to
the incidence of diabetes in young Spanish Caucasian
population (8 cases per 1000 person-year) (Valdes et al.,
2007; Soriguer et al., 2008). Our findings differ from
those reported in most previous studies which have
shown a higher risk of diabetes in patients treated with
first- or second-generation antipsychotics than in un-
exposed individuals (Baker et al., 2009; Kessing et al.,
2010; Nielsen et al., 2010; Mitchell et al., 2012). Two
major factors that could account for this discrepancy are
the relatively short exposure time to antipsychotic
therapy (3 yr) and the young mean age in our sample
(mean age at the end of the follow-up=30.5±7.5). Ethnic
differences may also contribute to explain the different
findings, as 98% of the sample was white Caucasian,
associated with a lower prevalence of diabetes than
other population groups.
Nevertheless, only 31% of the patients remained within
a normal BMI range at the end of the 3 yr. A high pro-
portion of them were exposed to high levels of triglycer-
ides (22.5%) and low levels of HDL-cholesterol (23%) and
two-thirds were smokers. Exposure to these risk factors
since early adulthood may have adverse consequences
on their long-term cardiovascular health.
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A recent publication (Foley and Morley, 2011) has sum-
marized CVD risk factors data from 25 longitudinal
studies of patients experiencing their first treated episode
of psychosis. The authors concluded that cardiovascular
risk increases after first exposure to any antipsychotic
drug. However, a definite conclusion about the impact
of antipsychotic therapy on cardiovascular risk at long
term was not possible to reach given the sparse data
beyond 1 yr, the high rates of dropouts in the longer trials
and the small sample size of most of these studies.
Strength and limitations
There are several limitations of this study. Firstly, adher-
ence to medication was self-reported and therefore may
have been over-estimated. Secondly, a comparison be-
tween treatments at long-term was not possible because
of the high percentage of treatment switching over the
3 yr period. Frequent changes in antipsychotic treatment
are a common pattern in clinical practice and this
means that in practice we cannot estimate the effects of
single antipsychotics on long-term cardiovascular mor-
bidity. Much larger samples will be needed to estimate
the effect of common and complex drug treatment pat-
terns used in clinical practice on long-term cardiovascular
outcomes. Thirdly, an important variable, blood pressure,
was not measured and a CVD risk score could not be
estimated.
However, the strengths of our study are also consider-
able. The sample studied was a cohort that was followed
for 3 yr, one of the longest follow-up studies in first-
episode medication-naive patients. The low numbers of
dropouts allowed us to accurately estimate the incidence
of metabolic adverse events in this population. Finally,
the high participation rate implies that the results are
generalizable to first-episode psychotic patients in our
geographic region.
Conclusion
In summary, the first year of exposure to antipsychotic
treatment is a critical period for development of obesity
and metabolic abnormalities. Early interventions to mod-
erate the rapid weight gain during the first mth of anti-
psychotic treatment could potentially help to reduce
the cardiovascular disease risks at long-term. Given the
high percentage of smokers, tobacco cessation interven-
tions should also be considered a priority for preventing
CVD. Moreover, specific interventions targeting this
group of people would be advisable as the smoking
rate is significantly higher than in the general population
of the same age (32.9 vs. 64%) and, as opposed to the
general population, it is not decreasing.
We are, however, cautious to generalize our findings
to other populations as they can be influenced by differ-
ent variables such as ethnic composition, prevalence of
obesity at baseline or adherence to medication. These
results need to be confirmed in larger prospective cohorts
from different cultural and ethnic groups.
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